Patients with blood group O have a lower risk of lymph node metastases but a higher risk of bilateral disease.
Patients with this malignancy had a 73% prevalence of simple renal cysts.
Recurrence that occurs more than 48 months after surgery is no longer significantly associated with reduced survival from renal cell carcinoma.
Researchers observe a high rate of local disease control with increased progression-free survival.
In a head-to-head trial, patients had similar progression-free survival with pazopanib and sunitinib, but experienced fewer adverse effects.
Renal cancers were found in 5% of patients with autosomal dominant polycystic kidney disease.
Bone metastases shorten progression-free and overall survival, study finds.
Study demonstrates improved disease-specific and overall survival.
Cancer-specific and the cancer-free survival rates were 99% at three and five years.
Risk is threefold greater when compared with partial nephrectomy.
It is associated with a high technical success rate and a low rate of complications; local recurrence rare.
After a median follow-up of 36 months, 98% of patients had no recurrence of small renal tumors.
For patients with metastatic disease receiving systemic treatment, a high BMI was found to improve overall survival.
Biopsy-proven renal cell carcinoma developed in 35 (0.5%) of 6,827 ESRD patients.
The survival advantage over men is greatest among women younger than 42 years.
Kidney cancer patients with both hypertension and diabetes are twice as likely to undergo nephron-sparing surgery as those with neither condition.
The 10-year overall survival rate was 94% for partial nephrectomy compared with 89.7% for radical nephrectomy in patients aged 20-44.
Relative survival rates for patients with advanced renal cell carcinoma have not improved significantly in the era of targeted agents.
Final overall survival data from a phase 3 trial reveal no significant difference between tivozanib and sorafenib.
A team of investigators suggests the use of two new specific targets for preventing metastasis in patients with clear cell renal cell carcinoma.
Microvascular invasion identified as risk factor for cancer-specific death.
The clinical trials needed to identify biomarkers are complex and difficult, British researcher says.
Many patients may be able to avoid extensive follow-up examinations.
Five-year overall and cancer-specific survival similar for patients with and without positive surgical margins.
Preoperative anemia associated with elevated risk of deaths from other illnesses.
Concomitant use of oral TKIs with bisphosphonates appear to be associated with improved outcomes in patients with RCC and bone involvement.
Although more blacks diagnosed with localized stage, smaller tumors, less aggressive subtype
The modality may provide a safe noninvasive treatment option.
Updated findings show overall survival in patients receiving the drugs as second-line treatment.
Pazopanib and sunitinib demonstrated similar progression-free and overall survival.